SCHEDULE 13G/A: BlackRock Discloses 6.5% Passive Stake in Capricor Therapeutics
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in Capricor Therapeutics Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Capricor Therapeutics Inc.
- As of December 31, 2024, BlackRock, Inc. beneficially owns 2,966,914 shares of Capricor Therapeutics Inc. Common Stock.
- This ownership represents 6.5% of the total outstanding shares of Capricor Therapeutics Inc.
- BlackRock holds sole voting power over 2,925,146 shares and sole dispositive power over 2,966,914 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
- BlackRock, Inc. is classified as a parent holding company or control person for the purpose of this filing.
- Several BlackRock subsidiaries and affiliates contribute to this aggregate beneficial ownership, with BlackRock Investment Management, LLC specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of passive ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral, reflecting a standard regulatory filing.
Positives
- The disclosure of a significant 6.5% stake by a major institutional investor like BlackRock, Inc. can be interpreted by the market as a vote of confidence in Capricor Therapeutics Inc.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a standard disclosure of passive institutional ownership and does not provide specific insights into Capricor Therapeutics Inc.'s operational performance or broader industry trends beyond the fact of significant institutional investment interest.
Stakeholder Impact
- Shareholders may view BlackRock's significant stake as a positive signal, potentially increasing investor confidence in Capricor Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-01-21 | Date of execution for the Power of Attorney document. |
| 2025-02-05 | Signature date of the Schedule 13G filing. |
Keywords
BlackRock, Capricor Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.